EP Mamounas

Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS

Irene Wapnir, James J. Dignam, Bernard Fisher et al. · JNCI Journal of the National Cancer Institute · 2011 · 774 citations · Full text

Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer

Edith A. Perez, Edward H. Romond, Vera J. Suman et al. · Journal of Clinical Oncology · 2007 · 217 citations

Surgical Oncology, Breast Oncology, Cancer Management +19

OT2-06-02: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women with Stage 0, 1, or 2 Breast Cancer: NSABP B-39/RTOG 0413.

TB Julian, J. P. Costantino, F.A. Vicini et al. · Cancer Research · 2011 · 102 citations

Surgical Oncology, Breast Oncology, Treatment Verification +19

Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

DJ Slamon, SM Swain, Marc Buyse et al. · Cancer Research · 2013 · 92 citations

Breast Oncology, Primary Results, Immunology +17

Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial.

Thomas B. Julian, J. P. Costantino, Frank A. Vicini et al. · Journal of Clinical Oncology · 2011 · 85 citations

Breast Oncology, Engineering, Nsabp B-39/rtog 0413 +19